HDM2012 / Huadong Medicine - LARVOL DELTA

Translational studies of HDM2012, a novel topoisomerase inhibitor ADC targeting MUC17, in patient derived GC, CRC, PDAC tumor models (AACR 2025) - "Here, we reporting a novel ADC product HDM2012 targeting MUC17, is a potential therapeutic approach for MUC17 positive GC, CRC, PDAC cancer treatment. All the experiment data indicated HDM2012 may be a promising candidate for GI cancer treatment."

Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • MUC17